Suppr超能文献

异烟肼和利福平联合化疗治疗肺结核

[Chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis].

作者信息

Kawakami Kenji

机构信息

Department of Respiratory Disease, Kawatana National Hospital, 2005-1, Shimogumi-go, Kawatana-cho, Higashisonogi-gun, Nagasaki 859-3615, Japan.

出版信息

Kekkaku. 2002 Aug;77(8):569-71.

Abstract

Two-drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three-drug or four-drug regimen containing chemotherapy pyrazinamide unless the prevalence of drug resistance, among new tuberculosis cases is low. We sent a questioners of 141 tuberculosis centers in Japan to investigate the rate of each standard chemotherapy regimen employed and reasons for selecting the two-drug regimen in each center. Of 3840 newly diagnosed cases in the 57 centers, 47.4% were treated with the four-drug regimen and 37.1% with the three-drug regimen, and two-drug regimen was employed in only 2.6%. Sputum smear-negative status was the major reason for selecting the two-drug regimen of chemotherapy. Though the two-drug regimen was used in few cases, taking into account the prevalence of primary resistance to isoniazid in Japan in 1997 was 4.4%, it was concluded to discontinue recommending the two-drug regimen as one of standard methods of treatment for pulmonary tuberculosis.

摘要

自1996年以来,异烟肼和利福平两药联合化疗方案一直是日本活动性肺结核的标准治疗方法之一,而美国胸科学会/美国疾病控制与预防中心(ATS/CDC)以及世界卫生组织/国际防痨和肺部疾病联盟(WHO/IUATLD)推荐使用含吡嗪酰胺的三药或四药化疗方案,除非新结核病例中的耐药率较低。我们向日本的141家结核病中心发放了调查问卷,以调查各中心采用每种标准化疗方案的比例以及选择两药方案的原因。在57个中心的3840例新诊断病例中,47.4%接受了四药方案治疗,37.1%接受了三药方案治疗,仅2.6%采用了两药方案。痰涂片阴性是选择两药化疗方案的主要原因。尽管两药方案的使用病例较少,但考虑到1997年日本异烟肼原发性耐药率为4.4%,得出的结论是停止将两药方案作为肺结核的标准治疗方法之一进行推荐。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验